Gabriel Kim

1.7k total citations · 1 hit paper
16 papers, 1.4k citations indexed

About

Gabriel Kim is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Gabriel Kim has authored 16 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Gabriel Kim's work include Diabetes Treatment and Management (10 papers), Pancreatic function and diabetes (9 papers) and Metabolism, Diabetes, and Cancer (6 papers). Gabriel Kim is often cited by papers focused on Diabetes Treatment and Management (10 papers), Pancreatic function and diabetes (9 papers) and Metabolism, Diabetes, and Cancer (6 papers). Gabriel Kim collaborates with scholars based in Germany, United States and France. Gabriel Kim's co-authors include Uli C. Broedl, Hans J. Woerle, Afshin Salsali, Michael Roden, Martin Ridderstråle, Cordula Zeller, Jianping Weng, Bruno Delafont, Knut Robert Andersen and Ante Jelaska and has published in prestigious journals such as Diabetes Care, Lab on a Chip and Nephrology Dialysis Transplantation.

In The Last Decade

Gabriel Kim

16 papers receiving 1.4k citations

Hit Papers

Improved Glucose Control With Weight Loss, Lower Insulin ... 2014 2026 2018 2022 2014 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
    2014 292 citations Julio Rosenstock, Ante Jelaska et al. Diabetes Care profile →

Peers

Gabriel Kim
Albert Fung United States
Heidrun Bosch‐Traberg Denmark
Bruce R. Leslie United States
Audrey Koitka‐Weber Germany
Sanbao Chai China
Erik J.M. van Bommel Netherlands
Aliza Rozenberg Israel
Ilan Yanuv Israel
Giulia Ferrannini Sweden
Ronnie Har Canada
Albert Fung United States
Gabriel Kim
Citations per year, relative to Gabriel Kim Gabriel Kim (= 1×) peers Albert Fung

Countries citing papers authored by Gabriel Kim

Since Specialization
Citations

This map shows the geographic impact of Gabriel Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Kim more than expected).

Fields of papers citing papers by Gabriel Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Kim. The network helps show where Gabriel Kim may publish in the future.

Co-authorship network of co-authors of Gabriel Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Kim. A scholar is included among the top collaborators of Gabriel Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Kim. Gabriel Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Aoun, Mabel, et al.. (2022). Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial. BMC Nephrology. 23(1). 100–100. 6 indexed citations
2.
Kim, Gabriel, et al.. (2021). Clues and new evidences in arterial hypertension: unmasking the role of the chloride anion. Pflügers Archiv - European Journal of Physiology. 474(1). 155–176. 7 indexed citations
3.
Kim, Gabriel, et al.. (2017). MP016HYPERCALCEMIA AND NEPHROCALCINOSIS INDUCED BY "PUMP AND POSE" INTRAMUSCULAR INJECTION. Nephrology Dialysis Transplantation. 32(suppl_3). iii434–iii434. 6 indexed citations
4.
Odonkor, Charles A., Gabriel Kim, & Michael Erdek. (2017). Global Cancer Pain Management: A Systematic Review Comparing Trials in Africa, Europe And North America. Pain Management. 7(4). 299–310. 6 indexed citations
5.
Köhler, Sven, Afshin Salsali, Stefan Hantel, et al.. (2016). Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Clinical Therapeutics. 38(6). 1299–1313. 81 indexed citations
6.
Roden, Michael, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology. 14(1). 154–154. 101 indexed citations
7.
Kovács, Christopher S., Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics. 37(8). 1773–1788.e1. 91 indexed citations
8.
Haering, Hans-Ulrich, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 110(1). 82–90. 67 indexed citations
9.
Rosenstock, Julio, Ante Jelaska, Guillaume Frappin, et al.. (2014). Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 37(7). 1815–1823. 292 indexed citations breakdown →
10.
Ridderstråle, Martin, Knut Robert Andersen, Cordula Zeller, et al.. (2014). Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology. 2(9). 691–700. 304 indexed citations
11.
Ridderstråle, Martin, et al.. (2014). Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM). Canadian Journal of Diabetes. 38(5). S56–S56. 4 indexed citations
12.
13.
Roden, Michael, Jianping Weng, Bruno Delafont, et al.. (2013). Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. 1(3). 208–219. 372 indexed citations
14.
Rosenstock, Julio, Ante Jelaska, Fei Wang, et al.. (2013). Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM). Canadian Journal of Diabetes. 37. S32–S32. 34 indexed citations
15.
Park, Jungyul, Deok‐Ho Kim, Gabriel Kim, et al.. (2010). Simple haptotactic gradient generation within a triangular microfluidic channel. Lab on a Chip. 10(16). 2130–2130. 19 indexed citations
16.
Kim, Gabriel, et al.. (2004). Vault Career Guide to Sales & Trading. Medical Entomology and Zoology. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Albert Fung Breakdown of academic impact, for papers by Heidrun Bosch‐Traberg Breakdown of academic impact, for papers by Bruce R. Leslie Breakdown of academic impact, for papers by Audrey Koitka‐Weber Breakdown of academic impact, for papers by Sanbao Chai Breakdown of academic impact, for papers by Erik J.M. van Bommel Breakdown of academic impact, for papers by Aliza Rozenberg Breakdown of academic impact, for papers by Ilan Yanuv Breakdown of academic impact, for papers by Giulia Ferrannini Breakdown of academic impact, for papers by Ronnie Har
Rankless by CCL
2026